Real-world Study on Characteristics of Traditional Chinese Medicine Syndromes of 50 Patients with Immune-related Adverse Events

LU Xingyu; ZHENG Jiabin; XUE Chongxiang; ZHANG Xu; YANG Meng; CHENG Zhiqiang; LI Liya; LOU Yanni; WANG Chao; CUI Huijuan

doi:10.13288/j.11-2166/r.2022.21.010

您当前的位置：

首页 >

文章列表页 >

Real-world Study on Characteristics of Traditional Chinese Medicine Syndromes of 50 Patients with Immune-related Adverse Events

更新时间：2022-10-27

- Real-world Study on Characteristics of Traditional Chinese Medicine Syndromes of 50 Patients with Immune-related Adverse Events
- Journal of Traditional Chinese Medicine Vol. 63, Issue 21, Pages: 2052-2059(2022)
- 作者机构：
  
  1.北京中医药大学，北京市朝阳区北三环东路11号，100029
  2.中日友好医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2022.21.010
  CLC：
- Received：14 January 2022，
  
  Revised：2022-06-24，
  
  Published：02 November 2022
- 稿件说明：
移动端阅览
鲁星妤,郑佳彬,薛崇祥等.50例免疫相关不良反应肿瘤患者中医辨证分型特点的真实世界研究[J].中医杂志,2022,63(21):2052-2059.

LU Xingyu,ZHENG Jiabin,XUE Chongxiang,et al.Real-world Study on Characteristics of Traditional Chinese Medicine Syndromes of 50 Patients with Immune-related Adverse Events[J].Journal of Traditional Chinese Medicine,2022,63(21):2052-2059.
鲁星妤,郑佳彬,薛崇祥等.50例免疫相关不良反应肿瘤患者中医辨证分型特点的真实世界研究[J].中医杂志,2022,63(21):2052-2059. DOI： 10.13288/j.11-2166/r.2022.21.010.

LU Xingyu,ZHENG Jiabin,XUE Chongxiang,et al.Real-world Study on Characteristics of Traditional Chinese Medicine Syndromes of 50 Patients with Immune-related Adverse Events[J].Journal of Traditional Chinese Medicine,2022,63(21):2052-2059. DOI： 10.13288/j.11-2166/r.2022.21.010.

摘要

目的

通过分析真实世界中肿瘤患者发生免疫相关不良反应（irAEs）的临床特征与中医分型，为中医药在irAEs中的临床应用提供参考。

方法

采取回顾性队列研究，收集采用免疫检查点抑制剂（ICIs）治疗并发生irAEs的肿瘤患者一般资料、ICIs应用类型、irAEs发生频次、严重程度分级情况、系统毒性等临床特征，并参考《恶性肿瘤中医诊疗指南》中医证型进行统一辨证。比较发生频次≥15%的主要中医证型各系统毒性构成比与总体证型构成比的差异，并对各激素使用方法、不同后续ICIs治疗情况之间的证型分布进行比较。

结果

共纳入50例患者，发生73次irAEs。证型组合发生频次从高到低依次为热毒证+痰湿证（34.3%）、气虚证+阴虚证（19.2%）、气虚证+痰湿证（15.1%）。皮肤毒性的辨证分型主要为热毒证+痰湿证（

=0.004），甲状腺功能减退的辨证分型以气虚证+阴虚证、气虚证+痰湿证为主（

=0.001），心脏毒性以气虚证+痰湿证为主（

=0.049），与整体证型分布比较，差异均有统计学意义。使用激素替代治疗的证型与非替代治疗的证型相比差异具有统计学意义，替代治疗以气虚证+阴虚证、气虚证+痰湿证为主（

=0.008）。不同后续ICIs治疗情况的辨证分型差异均无统计学意义（

＞0.05）。

结论

irAEs中医证型以热毒证+痰湿证表现的湿热相兼为主，同时存在气阴两虚证、气虚痰湿证等情况，可为中医药介入免疫治疗充分发挥辨证论治和个体化治疗优势提供依据与思路。

Abstract

Objective

To analyze the clinical characteristics and differentiated traditional Chinese medicine （TCM） syndromes of the real-world tumor patients who have had immune-related adverse reactions （irAEs）， thereby providing ideas for TCM in dealing with irAEs in clinical practice.

Methods

The general data， immune checkpoints inhibitors （ICIs） types， irAEs frequency， severity， systematic toxicity and other clinical characteristics of patients who have been treated by ICIs and have had irAEs were collected in a retrospective cohort design. The TCM syndromes were differentiated by referring to the

Malignant Tumor Diagnosis and Treatment Guideline with Chinese Medicine

. The ratio of each systemic toxicity component and the proportion of overall syndrome types were compared among TCM syndromes with frequency ≥15%. The syndrome type distribution between different hormone use methods and different subsequent ICIs treatment were compared.

Results

A total of 50 patients were included， with 73 irAEs. Heat-toxin syndrome plus phlegm-damp syndrome had highest frequency （34.3%）， followed by

deficiency syndrome plus

yin

deficiency syndrome （19.2%）， and

deficiency syndrome plus phlegm-damp syndrome （15.1%）. The main type of skin toxicity was heat toxin syndrome plus phlegm-damp syndrome （

= 0.004）， while that of hypothyroidism and cardiotoxicity were

deficiency syndrome plus

yin

deficiency syndrome and deficiency syndrome plus phlegm-damp syndrome （

= 0.001）， and

deficiency syndrome plus phlegm-damp syndrome （

= 0.049）， respectively. These results showed statistical differences when compared to overall syndromes distribution. The syndrome types of hormone replacement therapy was statistically different from those of non-replacement therapy， and

deficiency syndrome plus

yin

deficiency syndrome，

deficiency syndrome plus phlegm-damp syndrome were the main combinations of replacement therapy （

= 0.008）. There was no statistical difference in syndromes in terms of different follow-up ICIs treatment （

＞0.05）.

Conclusion

TCM syndrome of irAEs was mainly heat toxin syndrome plus phlegm-damp syndrome， characterized by damp and heat simultaneously， and

and

yin

deficiency syndrome and

deficiency and phlegm-damp syndrome may also be seen at certain time， giving full play to the advantages of syndrome differentiation and individual treatment of TCM when combining with immunological therapy.

关键词

Keywords

references

SANMAMED MF ， CHEN L . A paradigm shift in cancer immunotherapy： from enhancement to normalization ［J］. Cell ， 2018 ， 175 （ 2 ）： 313 - 326 .

XU C ， CHEN YP ， DU XJ ， et al . Comparative safety of immune checkpoint inhibitors in cancer： systematic review and network meta-analysis ［J］. BMJ ， 2018 ， 363 ： k4226 . doi： 10.1136/bmj.k4226 http://dx.doi.org/10.1136/bmj.k4226 .

WANG Y ， ZHOU S ， YANG F ， et al . Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials： a systematic review and meta-analysis ［J］. JAMA Oncol ， 2019 ， 5 （ 7 ）： 1008 - 1019 .

林洪生，张英 . 中医药与肿瘤：历史的积淀与五十年的创新发展［J］. 中国新药杂志， 2011 ， 20 （ 17 ）： 1639 - 1642 .

中国临床肿瘤学会指南工作委员会 . 免疫检查点抑制剂相关的毒性管理指南2021 ［M］. 北京：人民卫生出版社， 2021 ： 27 - 33 .

SHANKAR B ， ZHANG J ， NAQASH AR ， et al . Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer ［J］. JAMA Oncol ， 2020 ， 6 （ 12 ）： 1952 - 1956 .

林洪生 . 恶性肿瘤中医诊疗指南［M］. 北京：人民卫生出版社， 2014 .

DETTERBECK FC ， BOFFA DJ ， KIM AW ， et al . The eighth edition lung cancer stage classification ［J］. Chest ， 2017 ， 151 （ 1 ）： 193 - 203 .

MORAD G ， HELMINK BA ， SHARMA P ， et al . Hallmarks of response， resistance， and toxicity to immune checkpoint blockade ［J］. Cell ， 2021 ， 184 （ 21 ）： 5309 - 5337 .

DOUGAN M ， LUOMA AM ， DOUGAN SK ， et al . Understanding and treating the inflammatory adverse events of cancer immunotherapy ［J］. Cell ， 2021 ， 184 （ 6 ）： 1575 - 1588 .

RAMOS-CASALS M ， BRAHMER JR ， CALLAHAN MK ， et al . Immune-related adverse events of checkpoint inhibitors ［J］. Nat Rev Dis Primers ， 2020 ， 6 （ 1 ）： 38 .

ABDEL-RAHMAN O ， ELHALAWANI H ， FOUAD M . Risk of endocrine complications in cancer patients treated with immune check point inhibitors： a meta-analysis ［J］. Future Oncol ， 2016 ， 12 （ 3 ）： 413 - 425 .

NAIDOO J ， WANG X ， WOO KM ， et al . Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy ［J］. J Clin Oncol ， 2017 ， 35 （ 7 ）： 709 - 717 .

KHOJA L ， DAY D ， WEI-WU CHEN T ， et al . Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors： a systematic review ［J］. Ann Oncol ， 2017 ， 28 （ 10 ）： 2377 - 2385 .

GEISLER AN ， PHILLIPS GS ， BARRIOS DM ， et al . Immune checkpoint inhibitor-related dermatologic adverse events ［J］. J Am Acad Dermatol ， 2020 ， 83 （ 5 ）： 1255 - 1268 .

SZNOL M ， POSTOW MA ， DAVIES MJ ， et al . Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management ［J］. Cancer Treat Rev ， 2017 ， 58 ： 70 - 76 . doi： 10. 1016/j.ctrv.2017.06.002 http://dx.doi.org/10.1016/j.ctrv.2017.06.002 .

WANG DY ， SALEM JE ， COHEN JV ， et al . Fatal toxic effects associated with immune checkpoint inhibitors： a systematic review and meta-analysis ［J］. JAMA Oncol ， 2018 ， 4 （ 12 ）： 1721 - 1728 .

李要远，郑红刚，花宝金 . 运用扶正调气法论治肿瘤［J］. 中医杂志， 2022 ， 63 （ 6 ）： 588 - 591 .

刘清华，王璐璐 . 基于中医正邪学说关系浅析肿瘤免疫治疗的理论探讨［J］. 中医肿瘤学杂志， 2019 ， 1 （ 1 ）： 8 - 11 .

WEINMANN SC ， PISETSKY DS . Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors ［J］. Rheumatology （Oxford）， 2019 ， 58 （ Suppl 7 ）：vii59-vii 67 . doi： 10. 1093/rheumatology/kez308 http://dx.doi.org/10.1093/rheumatology/kez308 .

WEBER JS ， POSTOW M ， LAO CD ， et al . Management of adverse events following treatment with anti-programmed death-1 agents ［J］. Oncologist ， 2016 ， 21 （ 10 ）： 1230 - 1240 .

MOSLEHI JJ ， SALEM JE ， SOSMAN JA ， et al . Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis ［J］. Lancet ， 2018 ， 391 （ 10124 ）： 933 .

史珍，刘玉霞，蔡成森，等 . 免疫检查点抑制剂相关性肺炎的中医诊治探索［J］. 实用心脑肺血管病杂志， 2021 ， 29 （ 11 ）： 120 - 124 .

王翔宇，赵旭，朱学明，等 . 免疫检查点抑制剂所致皮肤免疫相关不良反应的中西医结合治疗［J］. 医药导报， 2022 ， 41 （ 3 ）： 323 - 326 .

吴利，彭玲，陈蓉 . 葛根芩连汤临床应用及实验研究进展［J］. 河南中医， 2021 ， 41 （ 4 ）： 527 - 531 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathogenesis and Treatment Approach of Cancer-Related Anorexia-Cachexia Syndrome Based on the Concept of "Blood Exhaustion" in The Inner Canon of Yellow Emperor （《黄帝内经》）

ZHAO Jifu's Experience in Treating Tumor Diseases with the Method of Resolving Toxins and Dissipating Masses

Strategies for the Syndrome Differentiation and Treatment of Malignant Tumors Based on the Theory of Stagnant Toxin

Whole Course Management and Therapeutic Strategy of Traditional Chinese Medicine for Thrombocytopenia Induced by Tumor Treatment

Implementation Thought of Integrated Traditional Chinese and Western Medicine for Tumor Full-cycle Prevention and Treatment from Precision Medicine

Related Author

ZHU Jinbiao

YUAN Mengyun

BAI Lu

NIE Duorui

WU Mianhua

YAN Yingjie

DING Dawei

GUO Jingyi

Related Institution

Nanjing University of Chinese Medicine

Jiangsu Province Hospital of Chinese Medicine

长春市中医院

Beijing University of Chinese Medicine

Dongzhimen Hospital，Beijing University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰